Prescribing information can be found at the bottom of the page

Bayer IUS supporting women's reproductive lifecycle and beyond

The Development and Evolution of Intrauterine Systems, Mirena (52mg levonorgestrel) IUS providing endometrial protection with oestrogen therapy and exploring the options for HMB (Heavy Menstrual Bleeding)

     

    Part 1 - The Development and Evolution of Intrauterine Systems

     
    Author/Uploaded by

    Dr Naomi Hampton, FRCOG FFSRH

     

    This recorded webinar is part of the “Women’s Health Matters” Medical Educational programme which aims to inspire, update and support healthcare professionals with an interest in women’s health.

     

    The webinar will cover:

    • The Development and Evolution of Intrauterine Systems

     

    Part 2 - The IUS and Contraception

     
    Author/Uploaded by

    By Dr Radhika Vohra, NHS and Private GP



     



    Learning objectives:




    • The contraceptive needs for younger patients
    • The effect of COVID-19 on contraception policy
    • What is Kyleena (19.5mg levonorgestrel) and when is it indicated?
    • Differences between Mirena (52mg levonorgestrel) and Kyleena (19.5mg levonorgestrel)
    • How to tackle common myths regarding IUDs
    • Factors affecting contraceptive choices in younger patients

     

    Part 3 - Mirena® (Levonorgestrel 52mg intrauterine delivery system) IUS to provide endometrial protection with oestrogen therapy

     

    Part 4 - Heavy menstrual bleeding (HMB): Exploring the options

    Watch now Watch now
    Part 1 - The Development and Evolution of Intrauterine Systems

    Dr Naomi Hampton, FRCOG FFSRH

      Watch now
    Part 2 - The IUS and Contraception

    Dr Naomi Hampton, FRCOG FFSRH

      Watch now
    Part 3 - Mirena® (Levonorgestrel 52mg intrauterine delivery system) IUS to provide endometrial protection with oestrogen therapy

    Dr Diana Mansour, Consultant in Community Gynaecology and Reproductive Health Care

    Watch now Watch now
    Part 4 - Heavy menstrual bleeding (HMB): Exploring the options

    Dr Aamena Salar, Medical Director Modality Community Services LLP GP Partner Modality Partnerships

    Our speakers

    Latest videos

    Menopause case 8 - Donna
    Watch now
    Making younger women aware of intrauterine contraception
    Watch now
    Developing an effective IUS/D service for 2021/2 and beyond
    Watch now

    RP-PF-WHC-GB-0979 May 2022

    Reporting adverse events and quality complaints

     

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.

     

    If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 011820‍63500 or email: pvuk@bayer.com

     

    Further information is available on the “contact” tab at www.bayer.co.uk.